New LaunchMay 18, 2026, 10:02 AM
Philips SmartIQ Reduces X-ray Dose by Over 50% for Coronary Imaging
AI Summary
Royal Philips announced SmartIQ, a breakthrough coronary imaging technology for its Azurion image-guided therapy, designed to improve image quality while significantly reducing X-ray radiation and contrast exposure. The technology includes an ultra-low dose protocol that employs over 50% less X-ray radiation dose for coronary procedures. A clinical pilot study published in JSCAI showed SmartIQ scored higher on image quality and was preferred in most blinded comparisons. SmartIQ is CE-marked and available in Europe and selected markets, with an ongoing RADIQAL trial further assessing its impact.
Key Highlights
- Philips SmartIQ reduces X-ray radiation dose by over 50% for coronary procedures compared to lowest ClarityIQ settings.
- First SmartIQ clinical pilot study published in JSCAI, showing higher image quality and preference in blinded comparisons.
- The ongoing RADIQAL trial, assessing SmartIQ's impact on radiation dose, has reached 60% enrollment and completed European sites.
- SmartIQ is CE-marked and available in Europe and selected markets on new and existing Azurion systems.
- The technology is not yet cleared for use in the United States.
Price Impact
More from PHG